{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:33:53Z","timestamp":1790627633304,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.urolonc.2021.04.011","type":"journal-article","created":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T23:45:21Z","timestamp":1622504721000},"page":"498.e1-498.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Evaluation of carbonic anhydrase IX as a potential therapeutic target in urothelial carcinoma"],"prefix":"10.1016","volume":"39","author":[{"given":"Tilman","family":"Todenh\u00f6fer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewan A.","family":"Gibb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Seiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Kamyabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Hennenlotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Moskalev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladan","family":"Fazli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoukat","family":"Dedhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnulf","family":"Stenzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Htoo Zarni","family":"Oo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2021.04.011_bib0001","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1038\/onc.2012.550","article-title":"Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche","volume":"32","author":"Lock","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.urolonc.2021.04.011_bib0002","doi-asserted-by":"crossref","first-page":"84","DOI":"10.18632\/oncotarget.422","article-title":"Recent developments in targeting carbonic anhydrase IX for cancer therapeutics","volume":"3","author":"McDonald","year":"2012","journal-title":"Oncotarget"},{"key":"10.1016\/j.urolonc.2021.04.011_bib0003","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.eururo.2014.04.007","article-title":"Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer","volume":"66","author":"Stewart","year":"2014","journal-title":"European Urol"},{"key":"10.1016\/j.urolonc.2021.04.011_bib0004","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/JTO.0000000000000148","article-title":"Membrane carbonic anhydrase IX expression and relapse risk in resected stage I-II non-small-cell lung cancer","volume":"9","author":"Stewart","year":"2014","journal-title":"J Thor Oncol"},{"key":"10.1016\/j.urolonc.2021.04.011_bib0005","doi-asserted-by":"crossref","first-page":"24856","DOI":"10.18632\/oncotarget.4498","article-title":"Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models","volume":"6","author":"Ward","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.urolonc.2021.04.011_bib0006","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/cncr.24163","article-title":"Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker","volume":"115","author":"Klatte","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2021.04.011_bib0007","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.eururo.2015.06.015","article-title":"Carbonic anhydrase IX as a diagnostic urinary marker for urothelial bladder cancer","volume":"68","author":"de Martino","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.04.011_bib0008","series-title":"International union against cancer (UICC): TNM classification of malignant tumors","author":"LH","year":"2002"},{"key":"10.1016\/j.urolonc.2021.04.011_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.urolonc.2021.04.011_bib0010","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.eururo.2017.03.021","article-title":"An oncofetal glycosaminoglycan modification provides therapeutic access to cisplatin-resistant bladder cancer","volume":"72","author":"Seiler","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.04.011_bib0011","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","article-title":"Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy","volume":"72","author":"Seiler","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.04.011_bib0012","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","article-title":"Comprehensive transcriptional analysis of early-stage urothelial carcinoma","volume":"30","author":"Hedegaard","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.urolonc.2021.04.011_bib0013","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1158\/1535-7163.MCT-12-1150","article-title":"Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer","volume":"12","author":"Gust","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.urolonc.2021.04.011_bib0014","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1158\/1535-7163.MCT-18-0107","article-title":"Selective inhibition of the lactate transporter MCT4 reduces growth of invasive bladder cancer","volume":"17","author":"Todenhofer","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.urolonc.2021.04.011_bib0015","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1158\/0008-5472.CAN-12-3979","article-title":"Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer","volume":"73","author":"Shiota","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2021.04.011_bib0016","doi-asserted-by":"crossref","first-page":"e59536","DOI":"10.1371\/journal.pone.0059536","article-title":"Ultrasound-guided intramural inoculation of orthotopic bladder cancer xenografts: a novel high-precision approach","volume":"8","author":"Jager","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.urolonc.2021.04.011_bib0017","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1158\/0008-5472.CAN-10-4261","article-title":"Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors","volume":"71","author":"Lou","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2021.04.011_bib0022","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.clon.2007.06.014","article-title":"Carbonic anhydrase IX expression and outcome after radiotherapy for muscle-invasive bladder cancer","volume":"19","author":"Sherwood","year":"2007","journal-title":"Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.04.011_bib0023","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/sj.bjc.6601260","article-title":"GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON","volume":"89","author":"Hoskin","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2021.04.011_bib0024","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3233\/BLC-150033","article-title":"Hypoxia marker GLUT-1 (Glucose transporter 1) is an independent prognostic factor for survival in bladder cancer patients treated with radical cystectomy","volume":"2","author":"Bostr\u00f6m","year":"2016","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.urolonc.2021.04.011_bib0025","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Cancer Genome Atlas Research N. Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2021.04.011_bib0026","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nrurol.2014.129","article-title":"Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer","volume":"11","author":"Choi","year":"2014","journal-title":"Nature Rev Urol"},{"key":"10.1016\/j.urolonc.2021.04.011_bib0027","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.urolonc.2021.04.011_bib0028","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","article-title":"Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy","volume":"72","author":"Seiler","year":"2017","journal-title":"Eur Urolo"},{"key":"10.1016\/j.urolonc.2021.04.011_bib0029","doi-asserted-by":"crossref","first-page":"13605","DOI":"10.1038\/srep13605","article-title":"Hypoxia-induced carbonic anhydrase IX facilitates lactate flux in human breast cancer cells by non-catalytic function","volume":"5","author":"Jamali","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.urolonc.2021.04.011_bib0030","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.4161\/cc.24902","article-title":"Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells","volume":"12","author":"Fiaschi","year":"2013","journal-title":"Cell Cycle"},{"key":"10.1016\/j.urolonc.2021.04.011_bib0031","doi-asserted-by":"crossref","first-page":"6160","DOI":"10.1158\/0008-5472.CAN-03-2224","article-title":"Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion","volume":"64","author":"Robertson","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2021.04.011_bib0032","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1021\/jm300529u","article-title":"Antimetastatic effect of sulfamate carbonic anhydrase IX inhibitors in breast carcinoma xenografts","volume":"55","author":"Gieling","year":"2012","journal-title":"J Med Chem"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392100168X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392100168X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:22:53Z","timestamp":1761042173000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107814392100168X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S107814392100168X"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.04.011","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of carbonic anhydrase IX as a potential therapeutic target in urothelial carcinoma","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}